The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Raxibacumab for the Treatment of Inhalational Anthrax
Open accessAbstract
BACKGROUND: Inhalational anthrax caused by Bacillus anthracis is associated with high mortality primarily due to toxin-mediated injury. Raxibacumab is a human IgG1lambda monoclonal antibody directed against protective antigen, a component of the anthrax toxin. METHODS: We evaluated the efficacy of raxibacumab as a prophylactic agent and after disease onset in a total of four randomized, placebo-controlled studies conducted in rabbits and monkeys. Animals were exposed to an aerosolized target exposure of B. anthracis spores that was approximately 100 times (in the prophylactic studies) and 200 times (in the therapeutic-intervention studies) the median lethal dose. In the therapeutic-intervention studies, animals were monitored for the onset of symptoms. Animals with detectable protective antigen in serum, a significant increase in temperature, or both received a single intravenous bolus of placebo or raxibacumab at a dose of either 20 mg per kilogram of body weight or 40 mg per kilogram. The primary end point was survival at day 14 (in rabbits) or at day 28 (in monkeys). Safety studies were conducted with intravenous raxibacumab (40 mg per kilogram) in 333 healthy human volunteers. RESULTS: In both rabbits and monkeys, the time to detection of protective antigen correlated with the time to bacteremia (r=0.9, P<0.001). In the therapeutic-intervention studies, the survival rate was significantly higher among rabbits that received raxibacumab at a dose of 40 mg per kilogram (44% [8 of 18]) than among rabbits that received placebo (0% [0 of 18]; P=0.003). Raxibacumab treatment also significantly increased survival in monkeys (64% [9 of 14], vs. 0% [0 of 12] with placebo; P<0.001). In human subjects, intravenous raxibacumab at a dose of 40 mg per kilogram had a half-life of 20 to 22 days and provided a maximum concentration of the drug in excess of levels that are protective in animals. Concentrations of raxibacumab provide a surrogate end point that should be predictive of clinical benefit. CONCLUSIONS: A single dose of raxibacumab improved survival in rabbits and monkeys with symptomatic inhalational anthrax. (ClinicalTrials.gov number, NCT00639678.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anthrax as a Biological Weapon, 2002: Updated Recommendations for Management
Inglesby, T. V., O'Toole, T., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Friedlander, A. M., Gerberding, J., Hauer, J., Hughes, J., et al. (2002) · JAMA · doi:10.1001/jama.287.17.2236 · Cited by 1,027
Bioterrorism-Related Inhalational Anthrax: The First 10 Cases Reported in the United States
Jernigan, J. A., Stephens, D. S., Ashford, D. A., Omenaca, C., Topiel, M. S., Galbraith, M., Tapper, M., Fisk, T. L., Zaki, S., Popovic, T., et al. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0706.010604 · Cited by 999
Investigation of Bioterrorism-Related Anthrax, United States, 2001: Epidemiologic Findings
Jernigan, D. B., Raghunathan, P. L., Bell, B. P., Brechner, R., Bresnitz, E. A., Butler, J. C., Cetron, M., Cohen, M., Doyle, T., Fischer, M., et al. (2002) · Emerging Infectious Diseases · doi:10.3201/eid0810.020353 · Cited by 709
Anthrax Toxin: Receptor Binding, Internalization, Pore Formation, and Translocation
Young, J. A. T., & Collier, R. J. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142728 · Cited by 601
Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979.
Abramova, F. A., Grinberg, L. M., Yampolskaya, O. V., & Walker, D. H. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2291 · Cited by 410
Postexposure Prophylaxis against Experimental Inhalation Anthrax
Friedlander, A. M., Welkos, S. L., Pitt, M. L. M., Ezzell, J. W., Worsham, P. L., Rose, K. J., Ivins, B. E., Lowe, J. R., Howe, G. B., Mikesell, P., et al. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1239 · Cited by 406
Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity
Maynard, J. A., Maassen, C. B. M., Leppla, S. H., Brasky, K., Patterson, J. L., Iverson, B. L., & Georgiou, G. (2002) · Nature Biotechnology · doi:10.1038/nbt0602-597 · Cited by 287
Systematic Review: A Century of Inhalational Anthrax Cases from 1900 to 2005
Holty, J.-E. C., Bravata, D. M., Liu, H., Olshen, R. A., McDonald, K. M., & Owens, D. K. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-4-200602210-00009 · Cited by 274
Anthrax toxin: a tripartite lethal combination1
Ascenzi, P., Visca, P., Ippolito, G., Spallarossa, A., Bolognesi, M., & Montecucco, C. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03609-8 · Cited by 137
Subramanian, G. M., Cronin, P., Poley, G. E., Weinstein, A., Stoughton, S. M., Zhong, J., Ou, Y., Zmuda, J. F., Osborn, B. L., & Freimuth, W. W. (2005) · Clinical Infectious Diseases · doi:10.1086/430708 · Cited by 95
Self-citationProject BioShield: What It Is, Why It Is Needed, and Its Accomplishments So Far
Russell, P. K. (2007) · Clinical Infectious Diseases · doi:10.1086/518151 · Cited by 51
Cited by
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance
Dickey, S. W., Cheung, G. Y. C., & Otto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.23 · Cited by 799
The past, present, and future of antibiotics
Cook, M. A., & Wright, G. D. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo7793 · Cited by 652
Alternative therapeutic strategies to treat antibiotic-resistant pathogens
MacNair, C. R., Rutherford, S. T., & Tan, M.-W. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00993-0 · Cited by 276
Metadata
- Authors
- Migone, T.-S., Subramanian, G. M., Zhong, J., Healey, L. M., Corey, A., Devalaraja, M., Lo, L., Ullrich, S., Zimmerman, J., Chen, A., Lewis, M., Meister, G., Gillum, K., Sanford, D., Mott, J., & Bolmer, S. D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-07-09
- Volume
- 361
- Issue
- 2
- Pages
- 135-144
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2084650506
- Cited by
- 294
- References
- 11
- FWCI
- 6.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.